Development · 30 Oct 2026
8 publishers have reported this development. Each act of reporting is below, cited.
Paras Healthcare's shares were listed on stock exchanges on October 28, at a premium of approximately 4% compared to its initial public offering (IPO) price.
Paras Healthcare shares made a positive debut on the stock exchanges, listing at nearly 4 per cent premium over the IPO issue price of Rs 693 per share on Wednesday, October 28, 2026.
The basis of allotment of Paras Healthcare IPO shares is expected to be finalised on Monday, October 26, 2026.
Paras Healthcare’s Rs 1,450-crore initial public offering was subscribed 2.23 times on Friday (October 23) with institutional and retail investors driving demand on the final day of bidding.
Paras Healthcare IPO received 34 percent subscription by 5:00 pm on October 22.
Paras Healthcare's Rs 1,450 crore IPO opened for subscription on October 21 and closes on October 23, with a grey market premium (GMP) of around 7%.
Paras Healthcare IPO opened on October 21, 2026.
Paras Healthcare IPO opens today.
Paras Healthcare has fixed the IPO price band at Rs 660-693 per share for its Rs 1,450 crore issue, which opens on October 21.
Paras Healthcare has fixed a price band of 660-693 per equity share for its initial public offering (IPO), which will be open for subscription from October 21-23.
Paras Healthcare has set its IPO price band at Rs 660-693 per share, targeting Rs 1,450 crore, opening October 21.
Paras Healthcare Ltd will launch its ₹1,450-crore initial public offering (IPO) on October 21, with a price band of ₹660-693 per share.
Paras Healthcare has fixed the price band for its IPO at ₹660–₹693 per share, with the issue opening on October 21 and closing on October 23.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.